OBJECTIVES: Panic disorder (PD) is an anxiety disorder, which occurs frequently in patients presenting to a First Heart Aid (FHA) with chest pain and/or palpitations. Although the efficacy of pharmacological treatment for PD in a psychiatric population is high, an accepted standard treatment for PD in cardiac patients is not yet available. The objective of this study was to evaluate the cost-effectiveness of pharmacological treatment compared to care as usual in patients presenting with cardiac complaints to a FHA in whom PD was confirmed. METHODS: The design was a randomised double-blind placebo-controlled study with an intervention group receiving sertraline or placebo (IG; N = 62) and a care as usual group (CAUG; N = 44). The study was performed from the societal perspective with a time horizon of 24 weeks. Costs were calculated using cost diaries and hospital data. Primary endpoint was successful treatment, defined as reduction of ≥50% of the number of panic attacks and/or a reduction of ≥50% on the Hamilton Depression Rating Scale (HAMD). Secondary endpoint was health state utility, obtained by the EQ-5D, which was used to calculate QALYs. Incremental cost-effectiveness ratios (ICERs) were calculated for both endpoints. Subsequently, bootstrap analyses were performed (1000 replications) to quantify the uncertainty around the ICERs. RESULTS: Baseline characteristics were comparable for both groups. A total of 67.7% of the patients in the IG was treated successfully versus 43.2% in the CAUG (P = .017). Mean QALY in the IG was 0.30, versus 0.29 in the CAUG. The incremental costs amounted to €-1361.47 (-4060, -1337) in favour of the IG. CON-CLUSIONS: Based on this preliminary analysis with unblinded data both ICERs indicated a dominance for IG. This was confirmed by the bootstrap results, with 84.1% and 66.7% of the cost-effectiveness pairs, based on respectively the primary and secondary endpoints, lying in the southeast quadrant.
OBJECTIVES:
The objectives of this study were to determine the prevalence and direct costs of anxiety disorders in the U.S. population. METHODS: Retrospective analysis was conducted of the 1999 Medical Expenditure Panel Survey (MEPS) . The MEPS collected data from a nationally representative sample of 24,618 respondents and from respondents' health care and insurance providers. Data extracted for this study included medical conditions and use and payments for medical care. Anxiety disorders were defined using the current Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) and were mapped to corresponding ICD-9-CM codes and included anxiety and panic disorders, stress disorders, obsessivecompulsive disorder, and phobias. Anxiety patients were identified using ICD-9-CM codes and direct costs were calculated using patient and third party payments for anxiety-related medical events by type of medical care. Sample estimates were weighted and projected to the population and 95% confidence limits were calculated using the Taylor expansion method. RESULTS: The prevalence of anxiety disorders was 4.04% or 11,163,423 individuals (95% C.L. = 3.64%, -4.44%). Total direct costs of anxiety disorders were $5,986,529,599. Prescription medications and office-based medical provider visits accounted for the largest proportions of direct costs, at $1,963,991,706 (mean = $58; 95% C.L. = $53, -$64) and $1,890,703,392 (mean = $67; 95% C.L. = $55, -$79), respectively. Inpatient stays represented $1,237,191,177 while home health care expenses were $708,555,879. Emergency department and outpatient services were each below $140 million. CONCLUSIONS: Affecting more than 11 million individuals with medical care costs of almost $6 billion, the impact of anxiety disorders was substantial. Prescriptions and medical provider visits were direct cost drivers, collectively accounting for more than 60% of total direct costs. However, expenditures on inpatient stays and home health care were sizeable, together representing nearly $2 billion or one-third of total direct costs. Additional measures should be considered to enhance diagnosis and treatment of anxiety and avert more costly medical care alternatives. 
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